$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study
The next time someone challenges the importance of NIH-funded research in drug development, you might want to point them to a new study that highlights the foundational role the Institutes plays in biopharma research.
The study — published in the Proceedings of the National Academy of Sciences — concludes that every one of the 210 new molecular entities approved by the FDA between 2010 and 2016 can source research back to NIH-funded work. That is especially important in figuring the public context of first-in-class work, where basic research played a significant role in the scientific understanding of the targets involved.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
